Product image of Icalziss (Calcium Chloride Dihydrate) supplied by GNH India

Icalziss

Active Ingredient:
Calcium Chloride Dihydrate
Origin:
EU

Icalziss (Calcium Chloride Dihydrate)

Calcium chloride dihydrate, the active ingredient in Icalziss, is an electrolyte presented as an aqueous solution for extracorporeal use. It helps restore calcium ion concentrations in patients who require rapid calcium supplementation, such as those undergoing dialysis or cardiac surgery.

GNH India supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Vantive Belgium

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icalziss is used to address calcium deficits in clinical situations that involve extracellular fluid electrolyte management.

  • Hypocalcemia: restores normal serum calcium levels in patients with acute or chronic low calcium.
  • Renal dialysis: provides calcium replacement during hemodialysis to prevent calcium loss.
  • Cardiac surgery: supports calcium‑dependent myocardial function during cardiopulmonary bypass.
  • Massive transfusion: corrects calcium depletion caused by citrate‑containing blood products.

How It Works

  • Calcium chloride dihydrate dissociates in solution to release calcium ions (Ca2+) and chloride ions. The free calcium ions increase extracellular calcium concentration, supporting calcium‑dependent enzymatic reactions, myocardial contractility, and neuronal transmission, thereby re‑establishing electrolyte balance in the bloodstream.

Side Effects

Calcium chloride dihydrate may cause a range of adverse reactions when administered intravenously.

Common Side Effects

  • Hypercalcemia: elevated serum calcium levels causing fatigue or nausea.
  • Infusion site irritation: redness, pain, or swelling at the injection site.
  • Hypotension: transient drop in blood pressure during rapid infusion.
  • Nausea or vomiting: gastrointestinal discomfort following administration.
  • Muscle cramps: involuntary contractions due to calcium fluctuations.

Serious or Rare Side Effects

  • Cardiac arrhythmias: irregular heart rhythms, especially in patients with pre‑existing heart disease.
  • Pulmonary edema: fluid accumulation in the lungs after large volume infusion.
  • Metabolic alkalosis: disturbance of acid‑base balance.
  • Severe hypercalcemia: neurological symptoms, confusion, or coma.
  • Anaphylactic reaction: rare allergic response requiring immediate medical attention.

Precautions & Warnings

When using Icalziss, clinicians should observe several safety measures.

  • Monitor serum calcium: check levels before, during, and after infusion.
  • Adjust dose in renal impairment: reduced clearance may increase calcium accumulation.
  • Cardiac disease caution: avoid rapid infusion in patients with known arrhythmias.
  • Avoid in hypercalcemia: contraindicated when calcium levels are already elevated.
  • Infusion rate control: administer slowly to minimize hypotension and irritation.
  • Store at ambient temperature below 25°C: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Calcium chloride dihydrate can interact with several medications, requiring careful management.

Major Interactions (Avoid)

  • Bisphosphonates: concurrent use may increase risk of hypocalcemia.
  • Thiazide diuretics: can potentiate hypercalcemia.
  • Vitamin D analogs: may exacerbate calcium overload.
  • Digitalis glycosides: elevated calcium can increase digitalis toxicity.
  • Loop diuretics: may alter calcium balance unpredictably.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: monitor blood pressure and renal function.
  • Antacids containing calcium: cumulative calcium load may require dose adjustment.
  • Calcium channel blockers: observe for additive cardiovascular effects.
  • Anticonvulsants (e.g., phenytoin): may affect calcium metabolism.
  • Proton pump inhibitors: potential impact on calcium absorption.

Frequently Asked Questions

Icalziss contains calcium chloride dihydrate and is used to replenish calcium ions in the extracellular fluid of patients who need rapid calcium supplementation, such as those with hypocalcemia, undergoing renal dialysis, or receiving massive transfusions.

When dissolved, calcium chloride dihydrate releases calcium ions (Ca2+) that increase serum calcium levels, supporting calcium‑dependent physiological processes like muscle contraction, nerve transmission, and blood clotting, thereby helping restore electrolyte balance.

The prescribed dose of Icalziss is determined by the treating clinician based on the patient’s serum calcium level, clinical condition, and route of administration. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for calcium chloride dihydrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Icalziss, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Icalziss provides calcium in a highly soluble chloride form suitable for rapid intravenous or extracorporeal administration, whereas oral calcium carbonate or citrate preparations are used for chronic supplementation. The chloride form allows immediate correction of calcium deficits in acute clinical settings.

Icalziss should be stored at ambient temperature below 25 °C, protected from moisture and direct sunlight, and kept in its original packaging until use. Follow any additional handling instructions provided on the product label.

Icalziss is administered extracorporeally, typically as an intravenous infusion. The infusion rate and concentration are set by the healthcare provider to match the patient’s clinical needs and to avoid rapid shifts in calcium levels.

Serious risks include hypercalcemia, cardiac arrhythmias, pulmonary edema, and severe allergic reactions. Monitoring serum calcium and cardiac status during and after infusion helps mitigate these risks.

Icalziss should not be used in patients with known hypercalcemia, severe renal impairment without dose adjustment, or in those who have had hypersensitivity reactions to calcium chloride. Contraindications must be evaluated by the prescribing clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Calcium Chloride Dihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT